Aug. 18 at 3:54 PM
$LGVN: Roth Capital cuts target to
$3 from
$10, citing dilution and Q2 results. From biotech hope to biotech nope.
$BMEA: H.C. Wainwright slashes target to
$4 from
$18, maintaining a Buy rating. Dilution concerns overshadow diabetes and obesity programs.
$LODE: Analysts slash outlook to
$4 as dilution reigns supreme. More shares, less value… and the moon keeps moving further away.
$CELC: Needham lowers target to
$70 from
$74, citing dilution concerns. Oncology dreams diluted by capital raises.
$LULU: JPMorgan downgrades to Neutral with a
$224 target, citing high valuation and slowing growth. Athleisure dreams on a treadmill.
